# Envafolimab Combined With Endostatin in Recurrent or Metastatic MSS-type Colorectal Cancer

> **NCT05551247** · PHASE2 · UNKNOWN · sponsor: **First Affiliated Hospital Xi'an Jiaotong University** · enrollment: 30 (estimated)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** Envafolimab
- **DRUG:** recombinant human endostatin (endostatin)

## Key facts

- **NCT ID:** NCT05551247
- **Lead sponsor:** First Affiliated Hospital Xi'an Jiaotong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-15
- **Primary completion:** 2023-06-28
- **Final completion:** 2024-06-28
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05551247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05551247, "Envafolimab Combined With Endostatin in Recurrent or Metastatic MSS-type Colorectal Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05551247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*